Autoimmune Phenomena After Acute Stroke "ARIMIS"

Completed

Phase N/A Results N/A

Trial Description

The damage of the brain parenchyma, as well as the stroke-induced dysfunction of the blood-brain-barrier can make previously hidden CNS antigens "visible", and can thus lead to the development of autoimmune mechanisms.
It seems plausible that stroke-associated immunodepression influences the development and the phenotype of these autoreactive immune responses.
This study will investigate whether cerebral ischemia leads to changes in the immune response, in particular to the development and/or proliferation of autoreactive effector T-cells and/or regulatory T-cells. Furthermore, the association between the severity and the phenotype of this autoimmune response and the clinical course, i.e. prognosis and mortality, will be investigated.

Conditions

Trial Design

  • Observation: Case Control
  • Perspective: Prospective
  • Sampling: Probability Sample

Trial Population

acute media infarct or intracerebral bleeding

Outcomes

Type Measure Time Frame Safety Issue
Primary autoantigen-specific T-cells in patients with acute media infarct within 36 h No
Primary leukocytes in patients with acute media infarct within 36 hours No
Secondary frequency and phenotype of CNS-autoreactive immune cells under the influence of immunodepression within 36 h, after day 3, 7, 90 and 180 No
Secondary clinical course, i.e. mortality and prognosis after day 90 and 180 No
Secondary clinical course, i.e. mortality and prognosis (measured by mod. Rankin Scale and Bartel Index) after day 90 and 180 No
Secondary clinical course, i.e. mortality and prognosis (measured by mod. Rankin Scale) after day 90 and 180 No
Secondary clinical course, i.e. mortality and prognosis (measured by Bartel Index) after day 90 and 180 No

Biospecimen Retention:Samples Without DNA - blood samples (serum and plasma)

Sponsors